Testing version — LOERadar is in active testing. Features and data may change.
HYTRIN (TERAZOSIN HYDROCHLORIDE) | LOERadar
HYTRIN
NDA
TERAZOSIN HYDROCHLORIDE | N020347 | ABBOTT LABORATORIES PHARMACEUTICAL PRODUCTS DIV
4 strengths0 unique patents0 unique exclusivities
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
Para IV certification filed but no ANDA patent litigation cases (NOS 835) matched from PACER. Litigation may be pending or filed under a different caption.
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (4)
Sort:
#001 — EQ 1MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
RLD
0 patents0 exclusivities▴
CAPSULE;ORAL | Approved: Dec 14, 1994
No patent or exclusivity listings for this strength.
#002 — EQ 2MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
RLD
0 patents0 exclusivities▾
CAPSULE;ORAL | Approved: Dec 14, 1994
#003 — EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
RLD
0 patents0 exclusivities▾
CAPSULE;ORAL | Approved: Dec 14, 1994
#004 — EQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**